Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving <sup>225</sup>Ac-PSMA-617 Radioligand Therapy

Sathekge, Mike; Bruchertseifer, Frank; Vorster, Mariza; O. Lawal, Ismaheel; Knoesen, Otto; Mahapane, Johncy; Davis, Cindy; Reyneke, Florette; Maes, Alex; Kratochwil, Clemens; Lengana, Thabo; L. Giesel, Frederik; Van de Wiele, Christophe; Morgenstern, Aliyah

doi:10.2967/jnumed.119.229229

Public

Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy

Published in Journal of Nuclear Medicine • May 17, 2019

Authors:

Mike Sathekge

Frank Bruchertseifer

Mariza Vorster

Abstract

Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experience with a series of 73 castration-resistant prostate carcinoma patients treated with 225Ac-PSMA-617, iden...

Subject

Medicine

Prostate cancer

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!